Emerging Perspectives on Beta-2 Microglobulin in Cirrhosis and Hepatocellular Carcinoma: A Review of Current Evidence

Authors

  • Ayman Fathy Elsayed Mohammed, Ahmed Fathy Gomaa, Ahmed Samy Ahmed Morsy, Marwa Mohammed Esawy, Said Abdelbaky Gad

Keywords:

Beta-2 Microglobulin , Cirrhosis, Hepatocellular Carcinoma

Abstract

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and represents a leading cause of cancer-related mortality worldwide. Approximately 80–90% of HCC cases occur in patients with underlying liver cirrhosis, which creates a unique and high-risk microenvironment characterized by chronic

References

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.

Downloads

Published

2024-06-20

How to Cite

Ayman Fathy Elsayed Mohammed, Ahmed Fathy Gomaa, Ahmed Samy Ahmed Morsy, Marwa Mohammed Esawy, Said Abdelbaky Gad. (2024). Emerging Perspectives on Beta-2 Microglobulin in Cirrhosis and Hepatocellular Carcinoma: A Review of Current Evidence. Journal of Computational Analysis and Applications (JoCAAA), 33(06), 2403–2413. Retrieved from https://eudoxuspress.com/index.php/pub/article/view/3368

Issue

Vol. 33 No. 06 (2024): JOCAAA

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.